Please assess the completion status of the following clinical trial:

Trial Title: Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 6 year~2. Symptomatic malaria infection, i.e. history of fever or presence of fever \>37.5°C~3. Microscopic confirmation of asexual stages of P. falciparum (may be mixed with non-falciparum species) with parasitaemia PFT≥5/500 WBC~4. Written informed consent given to participate in the trial~Exclusion Criteria:~1. Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age unless menstruating).~2. Female of 12 to 18 years of age~3. P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL).~4. Signs or symptoms indicative of severe malaria including:~   * Impaired consciousness (Blantyre Coma Score \<5 or Glasgow Coma Scale \<15)~  * Severe anaemia (Hb% \<5 mg/dl)~  * Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites~  * Respiratory distress~  * Severe jaundice~  * Haemodynamic shock~5. A full course of artemether-lumefantrine treatment in the previous 28 days~6. Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or anaphylaxis~7. History of splenectomy

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AL3days (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine 3 days
- AL5days (Type: EXPERIMENTAL): Artemether-lumefantrine 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).